Goldman upgraded Danaher from Neutral to Buy and set a new price target of $260.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/21/2025 | $260.00 | Neutral → Buy | Goldman |
| 3/14/2025 | $260.00 | Hold → Buy | Stifel |
| 2/3/2025 | Outperform → Mkt Perform | Raymond James | |
| 12/23/2024 | Sector Perform | Scotiabank | |
| 12/19/2024 | $275.00 | Buy | Guggenheim |
| 12/13/2024 | $290.00 | Neutral → Buy | BofA Securities |
| 10/31/2024 | $285.00 | Peer Perform → Outperform | Wolfe Research |
| 10/1/2024 | $315.00 | Overweight | Stephens |
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
Goldman upgraded Danaher from Neutral to Buy and set a new price target of $260.00
Stifel upgraded Danaher from Hold to Buy and set a new price target of $260.00
Raymond James downgraded Danaher from Outperform to Mkt Perform
WASHINGTON, March 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2025 on Tuesday, April 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. You
The new DxC 500i Analyzer Offers Flexibility and Scalability with Broad Chemistry and Immunoassay Assay Menu BREA, Calif., March 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the new DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay analyzer, received 510(k) clearance from the U.S. Food and Drug Administration. The DxC 500i combines advanced technology with an intuitive user interface, ensuring that laboratories of all sizes can meet the growing demands of modern healthcare. With throughput of up to 800 clinical chemistry tests per hour and 100 immunoassay tests per hour, this analyzer delivers precise and
WASHINGTON, Feb. 25, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conference in Boston, Massachusetts on Wednesday, March 5, 2025 at 10:30 a.m. ET. The event will be simultaneously webcast and can be accessed on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important h
WASHINGTON, March 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2025 on Tuesday, April 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. You
WASHINGTON, Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on April 25, 2025 to holders of record on March 28, 2025. This reflects an 18.5% increase over the previous dividend payment of $0.27. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - a
WASHINGTON, Jan. 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") today announced results for the fourth quarter and full year 2024. All results in this release reflect only continuing operations unless otherwise noted. Key Fourth Quarter 2024 Results Net earnings were $1.1 billion, or $1.49 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $2.14.Revenues increased 2.0% year-over-year to $6.5 billion and non-GAAP core revenue increased 1.0%.Operating cash flow was $2.0 billion and non-GAAP free cash flow was $1.5 billion.Key Full Year 2024 Results Net earnings were $3.9 billion, or $5.29 per diluted common share and non-GAAP ad
144 - DANAHER CORP /DE/ (0000313616) (Subject)
8-K - DANAHER CORP /DE/ (0000313616) (Filer)
10-K - DANAHER CORP /DE/ (0000313616) (Filer)
WASHINGTON, Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that it has appointed Charles Lamanna to its Board of Directors and to the Board's Science & Technology Committee. Mr. Lamanna is currently Corporate Vice President, Business & Industry Copilot at Microsoft (NASDAQ:MSFT), where he drives product innovation in AI-powered business applications, low-code platforms, and autonomous agents. He oversees the design, product development, and engineering of some of Microsoft's most transformative technologies, including Power Platform, Dynamics 365, and Copilot Studio. Prior to that, Mr. Lamanna was the founder and CEO of MetricsHub, one of the first public cloud
Patrick Merrin named Chief Operations Officer and Peter Fjellman named Chief Financial Officer Compass Minerals (NYSE:CMP), a leading global provider of essential minerals, today announced the appointment of Patrick Merrin, a seasoned operating executive in the mining industry, as the company's new chief operations officer (COO) and Peter Fjellman, who has decades of experience in senior finance roles, as its new chief financial officer (CFO). Merrin's appointment is effective March 3 and fills the COO position which has been open since June 2024. Fjellman, whose appointment is effective immediately, succeeds Jeff Cathey who has decided to depart Compass Minerals due to personal reasons.
DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics.Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together under a single roof.WASHINGTON, July 17, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher"), a global science and technology innovator, announced the launch of two new Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified labs intended to accelerate the development of Companion Diagnostics (C
SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)